cyrilzakka/clinical-trials huggingface dataset:
Study of the Relationship Between Blood Groups,RH and Skeletal Malocclusion : a Cross Sectional Study

the study is searching if there is a relationship between the blood groups and RH and the skeletal malocclusion using the skeletal class I as a control group

The study will be conducted on the patients seeking medical care in the orthodontic department Cairo University, for six months all patients with class II and class III malocclusion will be recruited based on Wits appraisal measured from the cephalometric X-ray taken routinely during orthodontic examination. Then a group of class I arch length discrepancy patients will be used as control. A blood sample will be withdrawn and taken to the Cairo university laboratory to analyze the blood group and RH .a statistical analysis will be performed to detect a relationship between skeletal malocclusion and the blood groups as compared to the control

Eligibility Criteria:
Inclusion Criteria:

skeletal class I,II and III patients non syndromic patients above the age of 18 no previous surgical intervention for correction of skeletal malocclusion

Exclusion Criteria:

* syndromic patients
* cleft patients
* patients with previous surgery to correct skeletal malocclusion
The Evaluation of Optimal Observation Period for Neurological Recovery in Post-arrest Survivors

To explore whether the patient's neurological function recovery period is sufficient after successful emergency resuscitation recommended by the current guidelines

The research team will collect patient data after successful emergency resuscitation after cardiac arrest in the emergency room of National Taiwan University Hospital, and will collect and analyze the relationship between the time for patients to regain consciousness and drug use, hemodynamic changes, and neurological examination results after resuscitation. To explore whether the patient population needs to extend the observation time of neurological function after a certain CPR emergency treatment, and allow the patient to have a longer observation period to regain consciousness.

Eligibility Criteria:
Inclusion Criteria:

* Patients with non-traumatic cardiac arrest in the emergency room of National Taiwan University Hospital (including pre-hospital cardiac arrest and in-hospital cardiac arrest) after successful emergency resuscitation

Exclusion Criteria:

* Under 20 years old
* Pregnant women
* Those who have not been admitted to the intensive care unit
* Unconsciousness before the heartbeat stops
* A clear consciousness after successful first aid resuscitation
Studies of the Pathogenesis of HIV Infection in Human Peripheral Blood Cells and/or Body Fluids in People Living With and Without HIV

We are studying virologic and/or immunologic parameters of HIV infection and other infectious or non-infectious immune deficiency diseases in order to better understand the pathogenesis of HIV. Because of the lack of an adequate animal model it is generally necessary to utilize human peripheral blood cells for studying aspects of either in vivo or in vitro HIV infection. We wish to be able to continue to elucidate many pathogenic aspects of HIV infection in relation to other infectious or non-infectious immune regulation and dysregulation using human peripheral blood mononuclear cells as a model.

We are studying virologic and/or immunologic parameters of HIV infection and other infectious or non-infectious immune deficiency diseases in order to better understand the pathogenesis of HIV. Because of the lack of an adequate animal model it is generally necessary to utilize human peripheral blood cells for studying aspects of either in vivo or in vitro HIV infection. We wish to be able to continue to elucidate many pathogenic aspects of HIV infection in relation to other infectious or non-infectious immune regulation and dysregulation using human peripheral blood mononuclear cells as a model.

Eligibility Criteria:
* INCLUSION CRITERIA:
* 18 years of age or older.
* Adequate venous access.
* Have a blood pressure less than or equal to 180/100: pulse rate 50-100, unless a lower pulse rate is considered normal for the volunteer.
* Have adequate blood counts (volunteers living with HIV: hemoglobin greater than or equal to 9.0 g/dL, platelets greater than or equal to 50,000; volunteers living without HIV: hemoglobin greater than or equal to 9.0 g/dL, platelets greater than or equal to 50,000
* Be willing and able to provide written informed consent on screening, comply with study requirements and procedures, and comply with clinic policies
* Willingness to allow blood samples to be used for future studies of HIV infection/pathogenesis, and undergo hepatitis screening

EXCLUSION CRITERIA:

* Pregnant and/or breastfeeding females.
* Active substance abuse or history of prior substance abuse that may interfere with protocol compliance or compromise volunteer safety.
Anti-inflammatory Effects of Intracoronary and Intravenous Abciximab Administration During Primary Percutaneous Coronary Intervention

Intracoronary abciximab administration during primary percutaneous coronary intervention (pPCI) could offer clinical advantages over the intravenous route. The aim of this study was to assess whether abciximab administration route could influence its anti-inflammatory effects. 87 consecutive STEMI patients candidate to pPCI were randomized to receive an intracoronary or intravenous abciximab bolus. The primary endpoint was the extent of inflammation, measured by C-reactive protein (CRP), VCAM-1 and ICAM-1 levels.

BACKGROUND: intracoronary abciximab administration during primary percutaneous coronary intervention (pPCI) could offer clinical advantages over the intravenous route. Besides antiplatelet effects, abciximab can modulate inflammation via cross-reactivity with GPIIb/IIIa, avb3, and aMb2 receptors. The aim of this study was to assess whether abciximab administration route could influence its anti-inflammatory effects.

METHODS: 87 consecutive STEMI patients candidate to pPCI were randomized to receive intracoronary (Group A, 47 patients) or intravenous (Group B, 42 patients) abciximab bolus. The primary endpoint was the extent of inflammation, measured by C-reactive protein (CRP), VCAM-1 and ICAM-1 levels.

Eligibility Criteria:
Inclusion Criteria:

* presence of STEMI according to the universal definition of myocardial infarction (7);
* hospital admission within 12 hours from symptom onset;
* successful treatment by primary PCI, defined as a procedure achieving infarct-related artery (IRA) patency with less than 10% residual coronary stenosis based on visual estimation.

Exclusion Criteria:

* age \> 90 years;
* cardiogenic shock at admission;
* left main as IRA;
* saphenous vein graft as IRA;
* previous PCI in the last 6 months;
* severe renal impairment (eGFR\<30ml/min) or dialysis treatment;
* thrombolytic drug administration in the last 30 days before admission;
* known malignancy diagnosed less than 5 years before admission;
* known active infectious, coagulative or systemic inflammatory diseases.
Use of Cysteamine in the Treatment of Cystinosis

Cystinosis is an inherited disease resulting in poor growth and kidney failure. There is no known cure for cystinosis, although kidney transplantation may help the renal failure and prolong survival. Both the kidney damage and growth failure are thought to be due to the accumulation of the amino acid cystine within the cells of the body. The cystine storage later damages other organs besides the kidneys, including the thyroid gland, pancreas, eyes, and muscle.

The drug cysteamine (Cystagon; ProCysBi) is an oral medication given to patients with cystinosis prior to kidney transplantation. The drug works by reducing the level of cystine in the white blood cells and muscle tissue. The drug may also decrease levels of cystine in the kidneys and other tissues.

This study has several goals:

1. Long-term surveillance of cysteamine treated patients.
2. Detection of new non-kidney complications of cystinosis.
3. Maintenance of a patient population for genetic testing (mutational analysis) of the cystinosis gene.\<TAB\>

Patients with nephropathic cystinosis have been treated with the cystine-depleting agent cysteamine since 1978. This therapy prevents or delays renal deterioration, improves growth, and depletes parenchymal tissues of cystine. Based largely upon data produced through this protocol, the Food and Drug Administration approved cysteamine bitartrate for use in cystinosis patients on August 15, 1994. Cysteamine is available as CystagonR through Mylan Pharmaceuticals in 50 mg and 150 mg capsules and as ProcysbiR in 75 mg capsules. By virtue of the current protocol, patients are admitted to the NIH Clinical Center for investigations every two years, except for cases of great interest or urgency. On each 1-3 day admission, a battery of tests is performed and the adequacy of cystine depletion by cysteamine is monitored. This protocol demonstrates the course of cystinosis patients treated with cysteamine, describes new complications of the disorder in poorly treated adults, and maintains NHGRI expertise in the field. Its monitoring and followup of patients over the course of 3 decades represents an invaluable contribution to our understanding of the natural history of this rare disease.

Eligibility Criteria:
* INCLUSION CRITERIA:

Diagnosis of cystinosis, whether classical or one of the variants with later onset or no renal complications.

Patients will be diagnosed as having cystinosis based upon a leucocyte cystine content greater than 1 nmol half-cystine/mg protein (normal, less than 0.2) and a typical clinical course.

EXCLUSION CRITERIA:

Inability to travel to the NIH.

Age less than one week.

Nonviable neonates and neonates of uncertain viability will be excluded.
Multicenter Study to Evaluate Safety and Efficacy of WC3011 (Estradiol Vaginal Cream) in Postmenopausal Women

The primary objective of this study is to compare the efficacy of WC3011 with placebo vaginal gel in postmenopausal women for the relief of vaginal dryness caused by vaginal atrophy as measured by self-assessment, vaginal pH and vaginal smear.


Eligibility Criteria:
Inclusion Criteria:

* Signed informed consent
* Moderate to severe vaginal dryness
* Postmenopausal meeting one of the following: 12 months spontaneous amenorrhea, 6 months spontaneous amenorrhea with serum Follicle-stimulating hormone (FSH) \> 40 milli-International Unit (mIU)/mL, 6 weeks postsurgical bilateral oophorectomy confirmed by surgical report, ultrasound or serum FSH \> 40 mIU/mL, 6 weeks postsurgical hysterectomy with ovary failure confirmed by serum FSH \> 40 mIU/mL
* Age ≥ 40 years or if bilateral oophorectomy ≥ 35 years
* Vaginal pH \>5.0
* Less than or equal 5% superficial cells on vaginal wall cytologic smear
* Normal breast exam; if \> 40 years, documentation of negative mammogram

Exclusion Criteria:

* Randomization in PR-04409, participation in clinical trial or use of investigational drug within 30 days prior to screening
* Smokes ≥ 15 cigarettes/day
* Known or suspected premalignant or malignant disease
* Cardiovascular disease, insulin-dependent diabetes mellitus, congestive heart failure, stroke or ischemic attack, thrombophlebitis or thromboembolic disorder
* Increased frequency/severity headaches with estrogen therapy
* Drug addiction/alcohol abuse within last 2 years
* Currently taking St. John's Wort or anticoagulant
* Uncontrolled hypertension or thyroid disorder, clinically significant depression or untreated urinary tract infection
Follow up by US Following Hospitalization With Periappendicular Abscess Refusing to be Operated on Within a Few Weeks.

Follow up via ultrasonic abdoman after patients who were giagnosed and treated as periappendicular abcess and refused to be operated later on in the "interval period ". To ass what occured to their appendics ?

During the last 10 years patients were hospitalized and treated with antibiotics due to the diagnosis of periappendicular abcess. they were invited to be operate after wards -appendectomy, electively few weeks later on. All these patients refused to be operated. What happend to their appendics few months or years later on via ultrasonic abdomen view??

Eligibility Criteria:
Inclusion Criteria:

* All patients diagnosed in the last 10 years suffering from periappendicular abcess.

Exclusion Criteria:

* after appendectomy
Cognitive-Behavioral Therapy for Young Adult Lesbian, Gay and Bisexual: Transdiagnostic Minority Stress Approach

Background: LGB people experience a large number of anxiety and mood disorders, and risk behaviors than heterosexual (Marshall et al., 2011). The evidence points to the importance played by the stress of minorities in the development of such problems (Bränstrom, Hatzenbuehler, Pachankis and Link, 2016).

Objective: The present study aims to adapt and analyze the efficacy of the ESTEEM program designed for this population (Burton, Wang and Pachankis, in press) in: 1) the reduction of psychopathological symptoms, abusive alcohol consumption and risky sexual behavior, 2 ) the decrease in the level of stress, anxiety for rejection, internalized homophobia and level of concealment, and finally, 3) the improvement of assertiveness levels. The effect of the variables social support, emotional regulation strategies and rumination will be analyzed.

Method: A quasi-experimental design will be used, where the LGB people (n = 63, 18\<) will be assigned to the experimental group (immediate treatment), or to the control group (three-month waitlist). At baseline, 3-month, 6-month and 12-month assessments, participants completed self-reports of mental health and minority stress.

Results: It is expected that after treatment, LGB people mental health will be improved, as well as, minority stress will be reduced.


Eligibility Criteria:
INCLUSION CRITERIA:

1. being born male and currently identifying as a man; or being born female and currentry identifying as a female
2. gay, lesbian or bisexual identity
3. minimum age 18

EXCLUSION CRITERIA:

1. not currently receiving regular mental health services
2. not having and addictive disorder
Cerebral Tissue Oxygenation in Highlanders/Lowlanders

The purpose of the current study is to evaluate the cerebral tissue oxygenation of Kyrgyz highlanders with high altitude pulmonary hypertension (HAPH) by performing a longitudinal cohort study. To this end, the investigators will invite the same highlanders who participated in the study in 2012 to undergo follow-up examinations in 2017, in order to allow comparisons of current results with baseline data from 2012.


Eligibility Criteria:
Inclusion Criteria:

* high altitude pulmonary hypertension confirmed by clinical presentation and mean pulmonary artery pressure \>30 mmHg measured by echocardiography at altitude of residence.
* healthy subjects (high altitude controls)
* Both genders
* Age \>16 y
* Kyrgyz ethnicity
* born, raised and currently living at \>2500 m
* healthy subjects currently living at \<1000 m (low altitude controls)

Exclusion Criteria:

* Pulmonary hypertension from other causes, in particular from left ventricular failure as judged clinically and by echocardiography
* Excessive erythrocytosis
* Other coexistent disorders that may interfere with the cardio-respiratory system and sleep
* Regular use of medication that affects control of breathing
* Heavy smoking
Effects of Inspiratory Muscle Training on Blood Pressure Levels in Hypertensive Individuals

This research aims to evaluate the effects of inspiratory muscle training (IMT) on blood pressure, in inspiratory muscle mechanoreflex, autonomic cardiovascular control in subjects with hypertension.

Patients with hypertension will be selected through the Outpatient Hypertension of the Hospital of Clinics de Porto Alegre, for convenience. Subsequently, patients will be subjected to test respiratory muscle strength (manometer), respiratory muscle resistance, cardiopulmonary exercise testing (maximum), evaluation of cardiac reflex sensitivity and autonomic control test and induction of inspiratory muscle mechanoreflex with occlusion plethysmography at baseline before the start of the training protocol. Patients will randomize inspiratory muscle training for 30 minutes a day, 7 days a week, for 8 weeks with muscle training device (PowerBreathe). There will be a weekly monitoring in the Clinical Research Center of the institution where the maximal inspiratory pressure (MIP) and respiratory training techniques will be reassessed and readjusted (40% of MIP). The control group will be submitted to respiratory training techniques with muscle training device (PowerBreathe) without load. After this period, all initial tests will be reassessed. A healthy control group study with 10 normotensive individuals will be included.

Eligibility Criteria:
Inclusion Criteria:

Participants will be selected from the medical records in search of Basic Health Unit and Hypertension Clinic - Hospital of Clinics of Porto Alegre (HCPA), Porto Alegre - RS:

* Diagnosis of essential hypertension with systolic blood pressure ≥140 mmHg and / or diastolic blood pressure ≥ 90 mmHg without treatment or use of antihypertensive;
* Only taking diuretics (monotherapy) or none;
* Body mass index ≤ 29.9 kg / m²;
* Not engaged in physical activity;
* Inspiratory muscle strength ≥ 70% of predicted.

  * Inclusion of normotensive individuals with systolic blood pressure \<130 mmHg and/or diastolic blood pressure \<85 mmHg by ambulatory blood pressure monitoring (ABPM).

Exclusion Criteria:

* Blood pressure ≥ 160/100 mmHg
* Pregnant and lactating women;
* Deep vein thrombosis; current or previous.
* Diabetes mellitus;
* Orthopedic impairments, musculoskeletal, neurological and / or cognitive impairment, or even other diseases that compromise participation in the proposed protocol;
* Acute myocardial infarction within the last 6 months;
* Hearth failure;
* Angina pectoris;
* Pulmonary impairment from any source;
* Current smoking.
Efficacy and Safety of Digital Therapeutic in Adults With Prediabetes

The study aims to evaluate the efficacy and safety of a digital therapeutic (TH-001) for adult individuals with prediabetes.


Eligibility Criteria:
Inclusion Criteria:

* Being diagnosed with prediabetes according to the ADA Prediabetes Diagnostic Criteria (the presence of at least one of the following criteria is sufficient for diagnosis: FBG 100 - 125 mg/dL, OGTT 2 hour BG: 140 - 199 mg/dL, HbA1c: 5.7% - 6.4)
* Not using medication for the treatment of prediabetes, and if so, taking a break for at least two weeks
* Having a smartphone with an iOS or Android operating system
* Being able to use a mobile application

Exclusion Criteria:

* Being diagnosed with diabetes mellitus
* Having a disease that can cause prediabetes
* Taking medication that may cause prediabetes
SZC Versus SPS for Treatment of Hyperkalemia in Hemodialysis Patients

This study aims to compare the effects of Sodium Zirconium Cyclosilicate versus Sodium Polystyrene Sulfonate for treatment of hyperkalemia in patients undergoing regular hemodialysis.

Patients maintained on regular hemodialysis (HD) have a high risk of hyperkalemia (\>5.0 mmol/l). Hyperkalemia is a critical medical condition that can result in arrhythmias and sudden cardiac death. Treatment of hyperkalemia in HD patients is challenging.

Therapeutic options for the treatment of hyperkalemia in HD population include potassium binding resins, such as sodium polystyrene sulfonate (SPS), patiromer, and sodium zirconium cyclosilicate. There is limited data about the use of these agents in HD.

Eligibility Criteria:
Inclusion Criteria:

1. ≥3 month of maintenance hemodialysis, 3 times per week for 4 hours.
2. Adult patients with age above 18 years.
3. baseline serum potassium level \>5 mEq/L.

Exclusion Criteria:

1. Gastrointestinal diseases (constipation, bleeding, Hx of endoscopy, chronic diarrhea or diarrhea in the past month, malabsorption, GIT surgery, ischemic colitis, necrosis, perforation, ....).
2. Breast feeding or pregnancy.
3. Patients who receive medications to treat hyperkalemia 2 weeks before study.
4. myocardial infarction, acute coronary syndrome, stroke, seizure, or thromboembolic event within 8 weeks before study.
Continuous Glucose Monitors to Regulate Glucose Levels in Type 2 Diabetics

This study allows Type 2 diabetics to receive feedback from a continuous glucose monitor (CGM) as part of an educational program designed to help them better manage their glucose levels. Subjects will also wear an activity tracker to monitor their activity and observe its effect on their glucose levels. The educational program will involve calls from coaches to check subjects' progress and answer questions.


Eligibility Criteria:
Inclusion Criteria:

* Be diagnosed with type 2 diabetes
* Currently take a DPP4 inhibitor, SGLT2 inhibitor, GLP-1 agonist, and/or basal insulin
* Be able to read and understand English
* Have access to a telephone
* Have a Medicare health plan

Exclusion Criteria:

* Pregnant
* Blind
* Deaf
* Currently receiving chemotherapy or radiation therapy to treat cancer
* Addicted to any drugs (including alcohol, painkillers, hallucinogens, or others)
* Critically ill
* Diagnosed with or experiencing:

  * Kidney disease stages 4 and 5
  * End stage renal disease
  * Severe liver disease
  * Dementia
  * Schizophrenia
  * Bipolar disorder
  * Autism
  * An intellectual or learning disability
  * Arrhythmias other than atrial fibrillation
  * Congestive heart failure
* Has had a:

  * Myocardial infarction within the last 6 months
  * Stroke within the last 6 months
  * Stroke that resulted in significant disability (e.g., unable to write clearly or walk)
Safety of GH001 in Healthy Volunteers

The aim of the study is to investigate the safety of GH001 (containing 5-methoxy-dimethyltryptamine; 5-MeO-DMT), and its dose-related psychoactive effects in healthy volunteers.

The study will evaluate single, ascending doses of GH001 in Part A and an individualized dosing regimen of GH001 in Part B.


Eligibility Criteria:
Inclusion Criteria:

* Subject has a body mass index (BMI) in the range of 18.5 and 27.0 kg/m2 (inclusive);
* Subject is in good general health in the opinion of the medical supervisor;
* Subject is in good mental health in the opinion of the (clinical) psychologist as determined by the intake interview;

Exclusion Criteria:

* Has known allergies or hypersensitivity or any other contraindication to 5-MeO-DMT;
* Has received any investigational medication within the last 1 month.
* Has a medically significant condition, which renders the subject unsuitable for the study.
Mechanism of Action of Electroconvulsive Therapy

This is an observational neuroimaging study assessing the effects of ECT on the brains of patients with unipolar and bipolar depression.

This project aims to use functional connectivity magnetic resonance imaging (fcMRI) to study patients with unipolar and bipolar depression receiving ECT. Patients will be scanned before and after a full course of ECT and clinical measures for depression severity and memory will be obtained at the same times.The project has the following aims and hypothesis: (1) to determine the therapeutic antidepressant mechanism of action of ECT at the circuit level (2) to determine the mechanism of action of iatrogenic amnesia caused by ECT at the circuit level (3) to study the use of fcMRI as a state biomarker for depression (4) to study the use of fcMRI as a predictor of response for depression.

Eligibility Criteria:
Inclusion Criteria:

* Males and Females Between Ages of 18 and 65
* Diagnosis of Major Depressive Disorder without Psychotic Features or Bipolar I/II
* Requiring ECT Treatment as Part of Psychiatric Care

Exclusion Criteria:

* Comorbid diagnoses of Major Depressive Disorder with Psychotic Features, Schizoaffective Disorder, Schizophrenia or Dementia
* History of Psychosis
* Substance Use Disorder (Abuse or Dependence) with Active Use Within Last 6 Months
* Severe or Unstable Medical Illness
* Medical Contraindication to Anesthesia or ECT (e.g., Recent Myocardial Infarction)